<DOC>
	<DOCNO>NCT01017770</DOCNO>
	<brief_summary>Several country Africa change first-line treatment uncomplicated malaria ACT . Burkina Faso change policy Artemether-Lumefantrine ( AL ) Artesunate-Amodiaquine ( AQ+AS ) . However , choice do without know local effectiveness drug give patient real life condition , without direct observation drug administration . Thus , study aim investigate effectiveness AQ+AS AL , give child uncomplicated malaria Burkina Faso .</brief_summary>
	<brief_title>Artemether-lumefantrine ( AL ) Versus Artesunate + Amodiaquine ( ASAQ ) Treatment Uncomplicated Falciparum Malaria Burkina Faso</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>Weight &gt; 5 kg ; Monoinfection P. falciparum parasitaemia 2,000200,000 parasite /µl ; Fever ( axillary temperature ≥37.5 °C ) history fever precede 24 hour ; Haemoglobin value 5.0 g/dl ; Absence febrile condition cause disease malaria . Danger sign : able drink breastfeed , vomit ( &gt; twice 24hours ) , recent history convulsion ( &gt; 1 24h ) , unconscious state , unable sit stand ; Signs severe malaria ( WHO 2000 ) ; Mixed malaria infection ; Severe malnutrition ; Other underlying disease ( cardiac , renal , hepatic disease ) ; History allergy study drug ;</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Uncomplicated malaria</keyword>
</DOC>